Skip to main content

Candel Therapeutics, Inc. (CADL)

NASDAQ: CADL · IEX Real-Time Price · USD
8.85 1.71 (23.95%)
Sep 21, 2021 3:47 PM EDT - Market open
Market Cap246.02M
Revenue (ttm)125,000
Net Income (ttm)-20.39M
Shares Out27.80M
EPS (ttm)-0.73
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume341,009
Open7.21
Previous Close7.14
Day's Range7.21 - 9.62
52-Week Range5.51 - 14.78
Betan/a
Analystsn/a
Price Target15.33 (+73.2%)
Est. Earnings DateNov 15, 2021

About CADL

Candel Therapeutics is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. We have established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. Our most adv...

IndustryBiotechnology
IPO DateJul 27, 2021
CEOPaul Peter Tak M.D., Ph.D. FMedSci
Employees41
Stock ExchangeNASDAQ
Ticker SymbolCADL
Full Company Profile

Financial Performance

Financial Statements

News

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherap...

1 week ago - GlobeNewsWire

Monday Afternoon Analyst Upgrades and Downgrades: Chesapeake Energy, Traeger and More

With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.

Other symbols:CHKCOOKNUVLRLYBRSKD
4 weeks ago - 24/7 Wall Street

Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters' Option

NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced ...

1 month ago - GlobeNewsWire

Candel Therapeutics Announces Pricing of Initial Public Offering

NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced ...

1 month ago - GlobeNewsWire

Candel Therapeutics IPO Registration Document (S-1)

Candel Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC